Urolithin A (often abbreviated as UA) is a small molecule produced when certain gut bacteria break down ellagic acid, a polyphenol found in foods such as pomegranates, berries, nuts and some grains. Unlike the parent compound, which is poorly absorbed, urolithin A can cross the intestinal barrier and reach tissues throughout the body, where it exerts biological effects that have attracted scientific interest.
Research over the past decade has moved urolithin A from a curiosity of food chemistry to a candidate for supporting cellular health. Studies in animals, cell cultures and, more recently, healthy volunteers have shown that UA can stimulate a process called mitophagy – the selective removal of damaged mitochondria – and improve several markers of metabolic and organ function. This article summarizes what urolithin A is, how it is made in the gut, the key mechanisms that have been documented, and what current human evidence tells us.
Key Takeaways
- Urolithin A is a gut‑derived metabolite of ellagic‑rich foods that can be absorbed and reach peripheral tissues.
- Its primary cellular action is to activate mitophagy, helping cells replace damaged mitochondria with healthier ones.
- Human trials to date show UA is safe, improves mitochondrial biomarkers, and may enhance muscle and metabolic health, but long‑term outcomes are still unknown.
- Advanced delivery forms (liposomes, gum‑arabic nanoparticles) increase UA stability and absorption in experimental settings.
- Pre‑clinical studies suggest organ‑specific protective effects (brain, liver, pancreas, heart), yet clinical confirmation is pending.
How Urolithin A Is Formed in the Body
Ellagic acid is a polyphenol that is abundant in pomegranate juice, strawberries, raspberries, walnuts and some oak‑derived foods. When these foods are eaten, ellagic acid reaches the colon largely unchanged because it is not well digested by human enzymes. Specific strains of gut bacteria, such as Gordonibacter spp., possess enzymes that convert ellagic acid into a series of metabolites called urolithins; the most studied of these is urolithin A [3].
The conversion depends on an individual’s microbial composition. Some people are “high producers” and generate measurable levels of UA in the bloodstream after a meal, while others produce little or none. The metabolite is then absorbed through the colon, travels via the portal vein to the liver, and is distributed to peripheral tissues where it can engage cellular pathways.
The Core Biological Action: Activating Mitophagy
Mitochondria are the power plants of the cell, but they accumulate damage with age or stress. Mitophagy is a quality‑control system that tags dysfunctional mitochondria for removal, allowing healthier organelles to take their place. Urolithin A has been shown to directly stimulate this pathway by activating the transcription factor PINK1 and the downstream protein Parkin, which together flag damaged mitochondria for degradation [2].
In a randomized, placebo‑controlled trial of middle‑aged adults, daily supplementation with UA for four weeks increased circulating markers of mitophagy and improved measures of mitochondrial respiration in muscle biopsies, without serious adverse events [2]. These findings suggest that UA can promote mitochondrial renewal in humans, a process that underlies many aspects of cellular vitality.
Beyond Mitochondria: Other Cellular Pathways Influenced by UA
While mitophagy is the most frequently highlighted mechanism, UA also interacts with other protective pathways. In mouse models, UA activates the Nrf2 antioxidant response, strengthening the gut barrier and reducing inflammation [1]. Liposomal formulations that improve UA stability have shown even greater bioavailability, further enhancing these effects in pre‑clinical studies [5].
Additionally, UA modulates lysosomal function, helping cells clear protein aggregates and damaged cellular components. This lysosomal rejuvenation was linked to cognitive benefits in a mouse model of Alzheimer’s disease, where UA treatment restored memory performance and reduced amyloid pathology [6].
Human Evidence: Safety, Bioavailability, and Early Health Signals
A systematic review of clinical investigations concluded that short‑term UA supplementation (up to 12 weeks) is well tolerated, with no serious adverse events reported across studies involving healthy adults and older volunteers [8]. The same review highlighted consistent improvements in biomarkers of mitochondrial function, muscle strength, and metabolic health, but noted that larger, longer trials are needed to confirm clinical relevance.
Bioavailability studies indicate that UA reaches peak plasma concentrations within 2–4 hours after oral intake, and that encapsulation technologies such as pH‑driven liposomes or gum‑arabic coated nanoparticles can further increase systemic exposure [PMID 37865359, PMID 42097775]. These delivery advances are important because the native compound is relatively unstable in the acidic stomach environment.
Potential Organ‑Specific Benefits Observed in Pre‑clinical Models
Several animal studies have explored how UA may protect specific organs. In a model of pancreatic injury, UA reduced inflammation and fibrosis, suggesting a protective role in pancreatic disease [4]. In chronic alcohol‑related liver disease, UA acted through the gut‑microbiota‑liver axis, improving liver histology and decreasing markers of oxidative stress, an effect that required the presence of the hepatokine MUP1 [7].
Cardiovascular toxicity from chemotherapy (cisplatin) was mitigated in mice by UA‑loaded nanoparticles, which dampened inflammation‑driven lymphangiogenesis and preserved cardiac function [9]. Although these findings are encouraging, they remain pre‑clinical and cannot be directly extrapolated to human disease.
Where to Find Urolithin A
- Urolithin A supplements on Amazon (generic, budget-friendly)
- Mitopure by Timeline (the clinically studied branded form)
As an Amazon Associate we earn from qualifying purchases.
A Note on the Evidence
Current evidence is limited to short‑term studies in healthy or at‑risk volunteers; UA should not replace medical treatment, and people with liver disease, pregnancy, or on medication should consult a healthcare professional before using supplements.
Frequently Asked Questions
How is urolithin A different from ellagic acid?
Ellagic acid is the plant‑derived precursor that is poorly absorbed; gut bacteria convert it into urolithin A, which is much more bioavailable and able to act on cellular pathways such as mitophagy [3].
Can I get enough urolithin A from diet alone?
Dietary intake of ellagic‑rich foods can produce UA in people who harbor the right gut microbes, but circulating levels vary widely. Supplementation provides a standardized dose and ensures exposure regardless of individual microbiota composition [3].
Is urolithin A safe to take?
Short‑term clinical studies (up to 12 weeks) have reported no serious adverse events and a good safety profile in healthy adults [PMID 39002645, PMID 32694802]. Long‑term safety has not been fully established.
Does urolithin A improve memory or treat Alzheimer’s disease?
In mouse models of Alzheimer’s, UA restored cognition and enhanced mitophagy and lysosomal function [6]. Human data are limited to biomarker studies; UA is not a proven treatment for dementia.
Who might benefit most from urolithin A supplementation?
Older adults or individuals with reduced mitochondrial efficiency may see measurable improvements in muscle performance and metabolic markers, as suggested by early human trials [PMID 32694802, PMID 39002645].
Do I need a special formulation to get the benefits?
Standard capsules deliver measurable UA, but formulations that protect UA from stomach acid—such as pH‑responsive liposomes or gum‑arabic coated nanoparticles—have shown higher bioavailability in experimental studies [PMID 37865359, PMID 42097775].
References
- Singh R et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nature communications (2019). PMID 30626868
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Zhang M et al. Ellagic acid and intestinal microflora metabolite urolithin A: A review on its sources, metabolic distribution, health benefits, and biotransformation. Critical reviews in food science and nutrition (2023). PMID 35142569
- Li K et al. Ameliorative Effects of Gut Microbial Metabolite Urolithin A on Pancreatic Diseases. Nutrients (2022). PMID 35745279
- Hu Y et al. Liposomes encapsulation by pH driven improves the stability, bioaccessibility and bioavailability of urolithin A: A comparative study. International journal of biological macromolecules (2023). PMID 37865359
- Hou Y et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimer's & dementia : the journal of the Alzheimer's Association (2024). PMID 38753870
- Zhang H et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis. Gut microbes (2024). PMID 38889450
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Wahab AT et al. Urolithin A-laden functional nanoparticles alleviate cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis. Free radical biology & medicine (2025). PMID 40516794
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.